Diadema Partners LP Blueprint Medicines Corp Transaction History
Diadema Partners LP
- $233 Billion
- Q4 2024
A detailed history of Diadema Partners LP transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Diadema Partners LP holds 64,193 shares of BPMC stock, worth $6.06 Million. This represents 2.4% of its overall portfolio holdings.
Number of Shares
64,193Holding current value
$6.06 Million% of portfolio
2.4%Shares
1 transactions
Others Institutions Holding BPMC
# of Institutions
380Shares Held
65.9MCall Options Held
1.6MPut Options Held
1.41M-
Vanguard Group Inc Valley Forge, PA6.77MShares$639 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$627 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.68MShares$536 Million0.06% of portfolio
-
Wellington Management Group LLP Boston, MA4.28MShares$404 Million0.07% of portfolio
-
State Street Corp Boston, MA2.5MShares$236 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.63B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...